$4.47
0.22% today
Nasdaq, Nov 20, 08:47 pm CET
ISIN
US83422E1055
Symbol
SLDB

Solid Biosciences Inc. Stock price

$4.48
-1.67 27.15% 1M
+1.58 54.48% 6M
+0.48 12.00% YTD
-0.63 12.33% 1Y
-2.34 34.31% 3Y
-44.87 90.92% 5Y
-334.82 98.68% 10Y
-334.82 98.68% 20Y
Nasdaq, Closing price Wed, Nov 19 2025
+0.01 0.22%
ISIN
US83422E1055
Symbol
SLDB
Industry

Key metrics

Basic
Market capitalization
$349.0m
Enterprise Value
$113.2m
Net debt
positive
Cash
$236.1m
Shares outstanding
77.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | 1,368.8
EV/Sales
- | 443.8
EV/FCF
negative
P/B
1.6
Financial Health
Equity Ratio
72.8%
Return on Equity
-91.1%
ROCE
-71.4%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $255.0k
EBITDA
$-168.0m | $-169.3m
EBIT
$-169.7m | $-169.9m
Net Income
$-167.1m | $-158.7m
Free Cash Flow
$-133.2m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-52.4% | -32.7%
EBIT
-50.9% | -30.7%
Net Income
-63.8% | -26.9%
Free Cash Flow
-45.2%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -66,385.3%
EBIT
-
Net
- | -62,220.2%
Free Cash Flow
-
More
EPS
$-1.8
FCF per Share
$-1.7
Short interest
13.6%
Employees
100
Rev per Employee
$0.0
Show more

Is Solid Biosciences Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,048 stocks worldwide.

Solid Biosciences Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a Solid Biosciences Inc. forecast:

18x Buy
95%
1x Hold
5%

Analyst Opinions

19 Analysts have issued a Solid Biosciences Inc. forecast:

Buy
95%
Hold
5%

Financial data from Solid Biosciences Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 37 37
19% 19%
-
- Research and Development Expense 133 133
64% 64%
-
-168 -168
52% 52%
-
- Depreciation and Amortization 1.66 1.66
24% 24%
-
EBIT (Operating Income) EBIT -170 -170
51% 51%
-
Net Profit -167 -167
64% 64%
-

In millions USD.

Don't miss a Thing! We will send you all news about Solid Biosciences Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Solid Biosciences Inc. Stock News

Neutral
GlobeNewsWire
3 days ago
- Non-exclusive license providing Solid's proprietary, next-generation capsid, AAV-SLB101, to Andelyn Biosciences, a full-service cell and gene therapy Contract Development and Manufacturing Organization (CDMO) - - AAV-SLB101 has been generally well tolerated in the 23 participants dosed in the Phase 1/2 INSPIRE DUCHENNE clinical trial as of a safety cutoff of October 31, 2025 -
Neutral
GlobeNewsWire
9 days ago
CHARLESTOWN, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences:
Neutral
GlobeNewsWire
14 days ago
- Innovation Passport award facilitates accelerated time to market and helps expedite patient access to transformative new medicines -
More Solid Biosciences Inc. News

Company Profile

Solid Biosciences, Inc. engages in the development of treatments for patients with Duchenne muscular dystrophy. It develops gene therapies, disease modifying therapies, and assistive devices for the cure of DMD. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Arnold, Annie Ganot and Gilad David Hayeem in March 2013 and is headquartered in Cambridge, MA.

Head office United States
CEO Alexander Cumbo
Employees 100
Founded 2013
Website www.solidbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today